LNK01001 Dose B

DRUG2 trials

Sponsors

Lynk Pharmaceuticals Co., Ltd

Conditions

Atopic DermatitisRheumatoid Arthritis

Phase 2

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

CompletedNCT06085521

Lynk Pharmaceuticals Co., LtdAtopic Dermatitis

Start: 2022-01-26End: 2023-06-14Updated: 2023-10-27

A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis

CompletedNCT06099535

Lynk Pharmaceuticals Co., LtdRheumatoid Arthritis

Start: 2021-11-18End: 2023-04-11Updated: 2023-10-25